Contextual Genomics and the Personalized Medicine Initiative Launch Phase 2 Testing of its National Access Program Cancer Genomics Test

1500 patients will be given access to the Find It™ hotspot cancer genomics test, which focuses on 90 known tumour mutations.
Vancouver, BC – March 14, 2016 – Contextual Genomics, developers of genomics-based cancer tests, and the Personalized Medicine Initiative (PMI), an organization bringing molecular-based medicine to Canadians, are pleased to announce they have launched the National Access Program’s Phase 2 Testing of its Find It™ (CG001) hotspot cancer panel genomics test.

The National Access Program’s Phase 2 testing involves using Find It™ hotspot cancer panel genomics test to analyze the solid tumours of 1,500 patients across Canada. The Find It™ hotspot panel screens for 90 of the most common mutations found in many cancers.  Based on the presence of a specific mutation in a cancer, healthcare providers can select the most appropriate treatment for the patient. The goal of the National Access Program is to make quality genomics testing widely available in cancer care to drive a shift towards personalized medicine and to support better health outcomes.

“We believe that quality genomic testing should become a standard practice in cancer care to give patients access to the most effective treatment option based on their tumour profile,” commented Chris Wagner, President and CEO of Contextual Genomics. “The National Access Program aims to make genomics cancer testing widely available in Canada. Our scientific expertise and CAP-accredited laboratory ensures that our genomics tests are of the highest standard of accuracy, relevance and safety,” he added.

Dr. David Huntsman, Chief Medical Officer of Contextual Genomics stated, “Contextual Genomics’ assays are designed to find the mutational information that oncologists and their patients need to make appropriate treatment decisions.”  He added, “Treatments are being developed which focus on specific abnormalities and the Find It™ genomics test provides a breadth of valuable data which will help to determine if a patient will respond and benefit from a specific treatment.”

For Phase 2 of the National Access Program, Find It™ hotspot panel will be provided free of charge to 1,500 patients. Test results will be given to the oncologist in a comprehensive clinical report. Healthcare professionals interested in enrolling their patient in the program can contact

About The National Access Program
The National Access Program for Cancer Testing, managed by the Personalized Medicine Initiative with testing provided by Contextual Genomics, provides a 90-mutation cancer genomics test to cancer patients across Canada. Each identified mutation is actionable with current medications or Phase 3 investigational treatments. As part of the program, real-time reports will be made available enabling patients and oncologists to make informed treatment decisions early.

Phase 2 of the program involves testing the tumours of 1,500 patients across the country, free of charge, to prospectively evaluate and match specific tumour types with approximately 40 therapy options. It is hoped that by understanding a patient’s personal genomic profile, both healthcare professionals and patients will be better equipped to diagnose and treat cancer. The goal of personalized medicine is to improve patient outcomes and reduce healthcare costs and adverse drug reactions.

Funding and technical assistance for the program are being provided by some of the world’s leading life science organizations including ArcherDx, AstraZeneca, Contextual Genomics, Illumina, LifeLabs, Pfizer, PMI, and Sanofi.

About Contextual Genomics:
Contextual Genomics is developing a novel suite of genomics-based cancer tests to identify a patient’s tumour profile. This precision in cancer diagnosis allows healthcare professionals to more accurately determine the most effective treatment options for the patient.  The company’s first products are actionable molecular tests that guide diagnosis and treatment of cancer.

Led by global leaders in molecular diagnostics, genomics and bioinformatics who have unparalleled expertise in genomic assay development, Contextual Genomics aims to bring patients a gold standard in molecular diagnostics that will lead to advanced services in personalized cancer care.

About Personalized Medicine Initiative:
The PMI is an inclusive organization representing stakeholders in BC and Canada that has the objective of bringing personalized, molecularly-based medicine to Canadians with the aim of improving healthcare outcomes and efficiency as well as enabling more effective preventive health delivery. The PMI is based at the Life Sciences Institute at UBC; Canada’s leading Life Sciences Institute.

Contextual Genomics
Chris Wagner, President and CEO

Personalized Medicine Initiative
Rob Fraser, PhD
COO, Personalized Medicine Initiative
Associate Director, Life Sciences Institute

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements